# Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease

> **NCT00868855** · PHASE1 · TERMINATED · sponsor: **Vanderbilt University** · enrollment: 16 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Bradykinin

## Key facts

- **NCT ID:** NCT00868855
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** poor enrollment
- **Last updated:** 2017-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00868855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00868855, "Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00868855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*